AMH, Dried Blood Spot ELISA

Home / Family / Reproductive Function / AMH, Dried Blood Spot ELISA

BACK

AMH, Dried Blood Spot ELISA

Product Search

Dried blood spot specimens stability makes it a practical alternative to venous blood. It opens new possibilities in AMH testing, such as comparison of historical to current patient results; simplified blood sampling for patients in remote locations or for those who are homebound. Instead of traveling to a clinic to get blood drawn, a blood spot sample can be taken at a convenient site and mailed to a laboratory. This technology will be especially useful for monitoring ovarian function of physically challenged cancer patients undergoing chemotherapy.

Specifications
Description
Citations
Documentation

Catalog Numbers	AL-129 (RUO) Instructions for Use AL-129-i (CE) Instructions for Use
Packaging	96 well microtiter
Detection	HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter
Dynamic Range	6, 4.4-989.8 pg/mL
Limit of Detection	1 Disk (7.9 mm) – 0.025 ng/mL, 2 Disks (7.9 mm) – 0.0125 ng/mL
Sample Size	1 Disk (7.9 mm) – 0.025 ng/mL, 2 Disks (7.9 mm) – 0.0125 ng/mL
Sample Type	extracted DBS sample
Assay Time	3.5 hours
Shelf Life	24 months
Species Reactivity	Human
Availability	Worldwide

Anti-Müllerian hormone (AMH), a member of the TGF-β superfamily, is a homodimeric glycoprotein composed of two 55 kDa N-terminal and two 12.5 kDa C-terminal homodimers, non-covalently linked by disulfide bridges.1

Recent studies have shown that the AMH C-terminal homodimer is much less active than the noncovalent complex, but almost all activity can be restored by associating with the N-terminal pro-region, which reforms a complex with the mature C-terminal homodimer. This finding raises the possibility that the AMH noncovalent complex is the active form of protein. It was reported that the cleaved AMH noncovalent complex binds to AMHRII and stimulates intracellular signaling, whereas full-length AMH shows only minimal activity.2

AMH is secreted by the Sertoli cells in males. During embryonic development, AMH is responsible for Müllerian duct regression. AMH continues to be produced by the testes until puberty and then decreases slowly to residual post-puberty values. In females, AMH is produced by the granulosa cells of small growing follicles from the 36th week of gestation onwards until menopause when levels become undetectable. Potential clinical applications of low end anti-müllerian hormone (AMH) have been published in premature ovarian insufficiency, ovarian tumors, menopause and many more.

References:
1. Pepinski, R.B., et al. (1988) J. Biol. Chem., 263, 18961-18964.
2. di Clemente et al. Mol Endocrinol, November 2010, 24 (11): 2193-2206.
3. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
4. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 – Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
5. Approved Guideline – Procedures for the Handling and Processing of Blood Specimens, H18-A3. 2004. Clinical and Laboratory Standards Institute.
6. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.

AMH (Dried Blood Spot) ELISA AL-129
Davidson S, Jahnke S, Jung AM, Burgess JL, Jacobs ET, Billheimer D, Farland LV. Anti-Müllerian Hormone Levels among Female Firefighters. Int J Environ Res Public Health. 2022 May 14;19(10):5981. doi: 10.3390/ijerph19105981. PMID: 35627519; PMCID: PMC9141260.